Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG
11 mars 2020 15h08 HE
|
CureVac AG
TÜBINGEN, Germany and BOSTON, March 11, 2020 (GLOBE NEWSWIRE) -- CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that company...
CureVac-CEO Daniel Menichella berät mit US-Präsident Donald Trump und Mitgliedern der Corona Task Force Entwicklungsmöglichkeiten eines Coronavirus-Impfstoffes
03 mars 2020 01h30 HE
|
CureVac AG
Weißes Haus hat Vertreter von Pharmaunternehmen zur Bekämpfung von Covid-19 eingeladenCureVac wählt derzeit aus Vielzahl von Impfstoffkandidaten die besten für klinische Tests ausGMP-zertifizierte...
CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. President Donald Trump and Members of Coronavirus Task Force
02 mars 2020 18h54 HE
|
CureVac AG
White House today invited representatives of pharmaceutical and biotech companies leading the COVID-19 response effortCureVac currently selecting best vaccine candidates for clinical trials from a...
Translate Bio Receives FDA Fast Track Designation for MRT5005 for the Treatment of Cystic Fibrosis
26 févr. 2020 07h30 HE
|
Translate Bio, Inc.
-- First inhaled mRNA therapeutic remains on track to report results from its ongoing multiple-ascending dose (MAD) portion of Phase 1/2 clinical trial in the third quarter of 2020 -- LEXINGTON,...
Aldevron Adds DasherGFP® mRNA to its Product Portfolio
12 févr. 2020 10h30 HE
|
Aldevron
Fargo, N.D., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins, mRNA and antibodies for the biotech industry, announced...
BioNTech plant öffentliches Angebot von American Depository Shares
03 févr. 2020 16h46 HE
|
BioNTech SE
MAINZ, Deutschland, Feb. 03, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) hat heute die Registrierungsdokumente (Form F-1) bei der amerikanischen...
BioNTech Announces Commencement of Public Offering of American Depositary Shares
03 févr. 2020 16h46 HE
|
BioNTech SE
MAINZ, Germany, Feb. 03, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today, that it has filed a registration statement on Form F-1 with the United...
CureVac berichtet positive Ergebnisse aus niedrig dosierter 1 µg Phase-1-Studie mit Tollwut-Impfstoff
07 janv. 2020 07h00 HE
|
CureVac AG
Impfung induziert selbst bei niedriger Dosierung bei sämtlichen Probanden eine Immunantwort und ist gut verträglich Klinische Ergebnisse unterstreichen Potenzial von CureVacs...
CureVac Announces Positive Results in Low Dose – 1 µg – Rabies Vaccine Clinical Phase 1 Study
07 janv. 2020 07h00 HE
|
CureVac AG
Low dose vaccination induced immune response in all subjects and was well tolerated Clinical results underline potency of CureVac’s technology platform Detailed results to be presented at an upcoming...
Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
19 déc. 2019 11h05 HE
|
CureVac AG
Company Announcement Genmab and CureVac enter broad strategic partnership Companies to conduct joint research on first program; option for Genmab to initiate three additional programs during 5-year...